1. Division of Genetics,
2. Howard Hughes Medical Institute and Department of Surgical Research, Children's Hospital, Boston, Massachusetts 02115 USA
3. Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA

Correspondence to: Louis M. Kunkel^1,2,3Richard C. Mulligan^2,3 Correspondence and requests for materials should be addressed to R.C.M. (Email: e-mail: mulligan@rascal.med.harvard.edu) or L.M.K. (Email: e-mail: kunkel@rascal.med.harvard.edu).

Abstract

The development of cell or gene therapies for diseases involving cells that are widely distributed throughout the body has been severely hampered by the inability to achieve the disseminated delivery of cells or genes to the affected tissues or organ¹. Here we report the results of bone marrow transplantation studies in the mdx mouse, an animal model of Duchenne's muscular dystrophy², which indicate that the intravenous injection of either normal haematopoietic stem cells or a novel population of muscle-derived stem cells into irradiated animals results in the reconstitution of the haematopoietic compartment of the transplanted recipients, the incorporation of donor-derived nuclei into muscle, and the partial restoration of dystrophin expression in the affected muscle. These results suggest that the transplantation of different stem cell populations, using the procedures of bone marrow transplantation, might provide an unanticipated avenue for treating muscular dystrophy as well as other diseases where the systemic delivery of therapeutic cells to sites throughout the body is critical. Our studies also suggest that the inherent developmental potential of stem cells isolated from diverse tissues or organs may be more similar than previously anticipated.